title: Effect of dipyridamole with or without aspirin on urine protein excretion in patients with membranous glomerulonephritis.
abstract: The antiproteinuric effect of the antiplatelet agent dipyridamole has been assessed after inhibition of thromboxane B2 (TxB2) synthesis in 8 patients with confirmed membranous glomerulonephritis. There were three study periods, each of 30 days, and 45 days apart, namely a washout period, treatment with dipyridamole 300 mg/d, and dipyridamole 225 mg/d plus aspirin 150 mg/d. On Days 1 and 30 of each study period serum and urine creatinine, 24-h excretion of protein, creatinine clearance, platelet aggregometry on whole blood and serum TxB2 were measured. Treatment with dipyridamole alone or with aspirin produced significant inhibition of platelet aggregation and a fall in 24-h protein excretion; the latter amounted to 54% with dipyridamole alone and 56% with dipyridamole plus aspirin (NS). Dipyridamole plus aspirin caused an 82% reduction in serum TxB2.
authors.affiliation: Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
authors.forename: J P
authors.initials: JP
authors.lastname: De La Cruz
authors.forename: S
authors.initials: S
authors.lastname: Cámara
authors.forename: M A
authors.initials: MA
authors.lastname: Frutos
authors.forename: F
authors.initials: F
authors.lastname: Sánchez De La Cuesta
mesh_terms: D000328:Adult; D001241:Aspirin / Q000627:therapeutic use*; D004176:Dipyridamole / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D007677:Kidney Function Tests; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011507:Proteinuria / Q000188:drug therapy* / Q000652:urine; D013928:Thromboxane A2 / Q000096:biosynthesis
chemical_list: D013928:Thromboxane A2; D004176:Dipyridamole; D001241:Aspirin